05/18/2022
Metastatic Prostate Cancer: Don’t Accept Complacency!
“This is all we can do” is a phrase no cancer patient wants to hear, especially someone with metastatic disease. Medical oncologist and PCF-funded investigator Andrew Armstrong, M.D., M.Sc., hears those six words a lot – from patients who have come to see him at Duke University’s Cancer Center, a. Read More
05/02/2022
Research Update from AACR 2022, Part 2
Research Update from AACR 2022, Part 2 The American Association for Cancer Research Annual Meeting 2022 was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. In Part 2, we highlight two. Read More
04/25/2022
Research Update from AACR 2022, Part 1: Spotlight on Immunotherapy
The American Association for Cancer Research Annual Meeting was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. This week, we highlight two presentations on potential ways to optimize the use of. Read More
03/29/2022
Highlights of ASCO GU 2022, Part 2
Informing care for intermediate-risk cancer, a new imaging tracer, and understanding the effects of PSA screening recommendations Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances. Read More
03/23/2022
Breaking News: First-in-Class Radioligand Therapy Approved for Advanced Prostate Cancer
What this means for patients: Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name PluvitcoTM) was approved by the FDA for certain patients with advanced prostate cancer. This medicine delivers a small dose of radiation attached to a molecule that specifically binds to prostate cancer cells. It has been shown to. Read More
03/08/2022
Highlights of ASCO GU 2022, Part 1
Combination treatments for metastatic disease Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances in screening, diagnosis, treatment, monitoring, and survivorship in prostate and other GU. Read More